Clinical Trials Browser

Withdrawn × HBI-8000 × Breast × Clear all

NCT02569489 2022-07-18

Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer

Phase 1 Withdrawn

Breast Neoplasms